2018 FINAL AGENDA

WEDNESDAY, NOVEMBER 14, 2018
(All Speakers Confirmed Unless Noted Otherwise)

WELCOME & INTRODUCTION
Michael McCaughan
Prevision Policy

HHS KEYNOTE ADDRESS (8:30-9:15)
HHS Deputy Secretary Eric Hargan

THE DRUG PRICING BLUEPRINT (9:15-9:45)
Deputy Assistant Secretary (Health Policy) for Planning and Evaluation John O'Brien
Prevision Policy’s Ramsey Baghdadi (Moderator)

ELECTION IMPACT ON 2019 (9:45-10:30)
Health Legislative Assistant, Sen. Orrin Hatch (R-Utah), Lauren Fleming Paulos
Health Policy Advisor, Sen, Michael Bennet (D-Col.), Rita Habib
Prevision Policy’s Michael McCaughan (Moderator)

CENTER DIRECTORS PANEL (10:30-11:30)
CDER Director Janet Woodcock
CBER Director Peter Marks
OCE Director Richard Pazdur
Friends of Cancer Research Chairperson and Founder Ellen Sigal (Moderator)

OMB OUTLOOK FOR 2019 (11:30-12:00)
OMB Associate Director, Health Programs Joe Grogan
Prevision Policy’s Ramsey Baghdadi (Moderator)

CMS KEYNOTE (Lunch Address)
CMS Administrator Seema Verma
Friends of Cancer Research VP-Public Affairs Ryan Hohman (Introduction)

THE BLUEPRINT: IMPACT ON MANUFACTURERS, PROVIDERS, & PATIENTS (1:15-2:15)
PhRMA VP-Policy & Research Randy Burkholder
Eli Lilly Senior Director Oncology Business, Corporate Affairs Jacqueline Zummo
Texas Oncology EVP-Policy & Strategic Initiatives Debra Patt
Friends of Cancer Research CEO Jeff Allen
ADVI Chief Innovation Officer Mike Kolodziej
ADVI CEO Marc Samuels (Moderator)

HOW TO SAVE ANTIBIOTICS (2:15-2:45)
Office of Antimicrobial Products Director Ed Cox
Prevision Policy’s Laura Helbling (Moderator)

BREAK (2:45:-3:00)

THE NEW OND (3:00-3:45)
FDA Office of New Drugs Deputy Director Peter Stein
Merck SVP-Global Regulatory Affairs & Clinical Safety Sandra Milligan
Greenleaf Health Principal John Jenkins
Prevision Policy’s Kate Rawson (Moderator)

FDA'S RISING STARS PANEL (3:45-5:00)
CDER Deputy Director for Clinical Science Bob Temple
Office of New Drugs Supervisory Medical Officer, Immediate Office, James Smith
OCE Deputy Director Amy McKee
Acting Director for the Office of Orphan Products Development Janet Maynard
Division of Neurology Products Director Billy Dunn
Prevision Policy’s Cole Werble (Moderator)